{
  "items": "25",
  "sentiment_score_definition": "x <= -0.35: Bearish; -0.35 < x <= -0.15: Somewhat-Bearish; -0.15 < x < 0.15: Neutral; 0.15 <= x < 0.35: Somewhat_Bullish; x >= 0.35: Bullish",
  "relevance_score_definition": "0 < x <= 1, with a higher score indicating higher relevance.",
  "feed": [
    {
      "title": "SeaStar Medical announces 1-for-10 reverse stock split effective Jan 5",
      "url": "https://www.investing.com/news/company-news/seastar-medical-announces-1for10-reverse-stock-split-effective-jan-5-93CH-4421856",
      "time_published": "20251223T220955",
      "authors": [
        "Investing.com"
      ],
      "summary": "SeaStar Medical Holding Corporation (NASDAQ:ICU) will enact a 1-for-10 reverse stock split on January 5, 2026, aiming to raise its share price above Nasdaq's $1.00 minimum bid requirement. This move follows an 87% stock price decline over the past year, with shares currently trading at $0.23. The company also recently reported third-quarter 2025 earnings showing significant revenue growth and progress in clinical trials for its acute kidney injury therapies.",
      "banner_image": "https://i-invdn-com.investing.com/news/world_news_2_69x52._800x533_L_1419494365.jpg",
      "source": "Investing.com",
      "category_within_source": "General",
      "source_domain": "Investing.com",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.809945"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.723225"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.614653"
        }
      ],
      "overall_sentiment_score": -0.603996,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "ICU",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.633522",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "SeaStar Medical stock tumbles after announcing 1-for-10 reverse split",
      "url": "https://www.investing.com/news/stock-market-news/seastar-medical-stock-tumbles-after-announcing-1for10-reverse-split-93CH-4421855",
      "time_published": "20251223T210955",
      "authors": [
        "Investing.com"
      ],
      "summary": "SeaStar Medical Holding Corporation (NASDAQ:ICU) shares plunged after the company announced a 1-for-10 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement. The split, effective January 5, 2026, was approved by stockholders and aims to boost the share price. Stockholders will receive one new share for every ten old shares, with proportional adjustments to outstanding options and warrants.",
      "banner_image": "https://i-invdn-com.investing.com/news/LYNXMPEA601E0_L.jpg",
      "source": "Investing.com",
      "category_within_source": "General",
      "source_domain": "Investing.com",
      "topics": [
        {
          "topic": "financial_markets",
          "relevance_score": "0.900882"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.807296"
        }
      ],
      "overall_sentiment_score": -0.722609,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "ICU",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.706585",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "Why this medical company is turning 10 shares into 1 to stay on Nasdaq",
      "url": "https://www.stocktitan.net/news/ICU/sea-star-medical-announces-1-for-10-reverse-d5wa1bz10af9.html",
      "time_published": "20251223T210955",
      "authors": [
        "NULL"
      ],
      "summary": "SeaStar Medical (Nasdaq: ICU) announced a 1-for-10 reverse stock split, effective January 5, 2026, to increase its market price and regain compliance with Nasdaq's $1.00 minimum bid requirement. This action will consolidate every 10 pre-split shares into 1 post-split share, affecting outstanding stock options and warrants proportionally, with a new CUSIP number assigned. The company's fundamentals, including FDA approval for its QUELIMMUNE (SCD-PED) therapy and Breakthrough Device Designation for six indications, remain unchanged.",
      "banner_image": "https://ml.globenewswire.com/media/MmViNWQ1MTAtYTZkYi00MmZiLTg3YTEtMTNmZWYyMzMwOGM1LTEzMTEwODMtMjAyNS0xMi0yMy1lbg==/tiny/SeaStar-Medical.png",
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.903486"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.822039"
        }
      ],
      "overall_sentiment_score": 0.032216,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ICU",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.030817",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Baird Jennifer a, director at Seastar Medical, buys $987 in stock",
      "url": "https://m.investing.com/news/insider-trading-news/baird-jennifer-a-director-at-seastar-medical-buys-987-in-stock-93CH-4420455?ampMode=1",
      "time_published": "20251223T001025",
      "authors": [
        "Investing.com"
      ],
      "summary": "Jennifer A Baird, a director at SeaStar Medical Holding Corp (NASDAQ:ICU), purchased 4,200 shares totaling $987 on December 19, 2025. This insider acquisition comes as ICU shares have significantly declined over the past year and week. SeaStar Medical is undergoing strategic changes, including a reverse stock split, reduced FDA registry enrollment, and a new CFO appointment.",
      "banner_image": "NULL",
      "source": "Investing.com",
      "category_within_source": "General",
      "source_domain": "Investing.com",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.932208"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.808973"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.714922"
        },
        {
          "topic": "ipo",
          "relevance_score": "0.619815"
        },
        {
          "topic": "finance",
          "relevance_score": "0.617839"
        }
      ],
      "overall_sentiment_score": 0.251655,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ICU",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.295893",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "SeaStar Medical shareholders approve 1-for-10 reverse stock split and authorized share reduction",
      "url": "https://www.investing.com/news/sec-filings/seastar-medical-shareholders-approve-1for10-reverse-stock-split-and-authorized-share-reduction-93CH-4416135",
      "time_published": "20251218T220845",
      "authors": [
        "Investing.com"
      ],
      "summary": "SeaStar Medical Holding Corp (NASDAQ:ICU) shareholders have approved a 1-for-10 reverse stock split and a reduction in authorized shares, effective January 2, 2026. This move will consolidate every 10 shares into one, with fractional shares rounded up, and decrease the total authorized shares by 25 million to 425 million. The company recently announced significant growth, clinical trial advancements, FDA approval for reduced enrollment in its SAVE Surveillance Registry, and appointed Michael Messinger as the new CFO.",
      "banner_image": "https://i-invdn-com.investing.com/news/World_News_9_800x533_L_1420026261.jpg",
      "source": "Investing.com",
      "category_within_source": "General",
      "source_domain": "Investing.com",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.904548"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.849888"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.725590"
        }
      ],
      "overall_sentiment_score": 0.143619,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ICU",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.129175",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "SeaStar Medical Announces FDA Approval of Reduction in Mandatory Enrollment for SAVE Surveillance Registry Evaluating QUELIMMUNE\u2122 Safety for Pediatric AKI",
      "url": "https://finance.yahoo.com/news/seastar-medical-announces-fda-approval-132700462.html",
      "time_published": "20251203T090953",
      "authors": [
        "NULL"
      ],
      "summary": "SeaStar Medical (Nasdaq: ICU) announced FDA approval to reduce the mandatory patient enrollment for its SAVE Surveillance Registry from 300 to 50 patients for the QUELIMMUNE\u2122 therapy, which treats pediatric acute kidney injury (AKI) with sepsis. This decision, based on promising safety and efficacy data from the initial 21 patients, is expected to accelerate adoption and expand market opportunities for the life-saving treatment which has shown a 70% survival rate at 90 days. The FDA's reduced requirement indicates confidence in the device's safety profile, allowing broader access to this critical therapy for pediatric AKI patients.",
      "banner_image": "NULL",
      "source": "Yahoo Finance",
      "category_within_source": "General",
      "source_domain": "Yahoo Finance",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.835399,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ICU",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.848131",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "SeaStar Medical (Nasdaq: ICU) gets FDA nod as SAVE registry cut to 50 patients",
      "url": "https://www.stocktitan.net/news/ICU/sea-star-medical-announces-fda-approval-of-reduction-in-mandatory-8uiw4khfurnr.html",
      "time_published": "20251203T041056",
      "authors": [
        "NULL"
      ],
      "summary": "SeaStar Medical announced that the FDA approved reducing the mandatory enrollment for its SAVE Surveillance Registry for QUELIMMUNE, a pediatric AKI therapy, from 300 to 50 patients. Early data from the 32 patients enrolled so far shows zero device-related adverse events and improved survival rates. This reduction is expected to ease the adoption and commercial rollout of QUELIMMUNE, which targets an estimated $100 million U.S. pediatric AKI market.",
      "banner_image": "https://ml.globenewswire.com/media/Yzc3YjRjNDMtNWEwMy00MTNhLTlmOTAtYTdlYTlkY2RkOTg3LTEzMTEwODMtMjAyNS0xMi0wMi1lbg==/tiny/SeaStar-Medical.png",
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.490407,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ICU",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.488994",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "SeaStar Medical Announces FDA Approval for Reduced Patient Surveillance Requirement in SAVE Registry, Enhancing QUELIMMUNE Market Potential",
      "url": "https://www.quiverquant.com/news/SeaStar+Medical+Announces+FDA+Approval+for+Reduced+Patient+Surveillance+Requirement+in+SAVE+Registry%2C+Enhancing+QUELIMMUNE+Market+Potential",
      "time_published": "20251202T133000",
      "authors": [
        "NULL"
      ],
      "summary": "SeaStar Medical announced FDA approval to reduce the SAVE Surveillance Registry enrollment from 300 to 50 patients for its QUELIMMUNE therapy. This reduction, based on positive safety data from initial patients showing zero device-related adverse events and improved survival rates, is expected to accelerate the therapy's adoption for pediatric acute kidney injury (AKI) and sepsis. The company anticipates this will enhance market penetration and expand access to this life-saving treatment.",
      "banner_image": "NULL",
      "source": "Quiver Quantitative",
      "category_within_source": "General",
      "source_domain": "Quiver Quantitative",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.921567"
        },
        {
          "topic": "finance",
          "relevance_score": "0.712004"
        }
      ],
      "overall_sentiment_score": 0.403196,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ICU",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.434456",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "SeaStar Medical to Present at Upcoming NobleCon21 Investor Conference",
      "url": "https://finance.yahoo.com/news/seastar-medical-present-upcoming-noblecon21-145200474.html",
      "time_published": "20251124T041056",
      "authors": [
        "NULL"
      ],
      "summary": "SeaStar Medical Holding Corporation announced that its CEO, Eric Schlorff, will present at NobleCon21 on December 3rd, 2025, at 4:00 PM EST. The company is a commercial-stage healthcare firm focusing on treatments for critically ill patients with organ failure. The presentation replay will be available online for 30 days starting December 4th.",
      "banner_image": "https://s.yimg.com/ny/api/res/1.2/rj0Ta3GGeVAy26gXI.Thag--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIyNDtoPTQ4O2NmPXdlYnA-/https://s.yimg.com/os/creatr-uploaded-images/2025-08/b2b7bbc0-8385-11f0-977e-d9d7d4cd04d2",
      "source": "Yahoo Finance",
      "category_within_source": "General",
      "source_domain": "Yahoo Finance",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.931926"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.739260"
        }
      ],
      "overall_sentiment_score": 0.425991,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ICU",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.411135",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "SeaStar Medical (Nasdaq: ICU) to present at NobleCon21 emerging growth conference",
      "url": "https://www.stocktitan.net/news/ICU/sea-star-medical-to-present-at-upcoming-noble-con21-investor-k47spg4ncdet.html",
      "time_published": "20251120T090953",
      "authors": [],
      "summary": "SeaStar Medical (Nasdaq: ICU) announced that CEO Eric Schlorff will present at the NobleCon21 emerging growth equity conference on December 3, 2025, at Florida Atlantic University. The presentation will be available for replay on the company's website starting December 4, 2025, for 30 days. The company, focused on treatments for critically ill patients with organ failure, recently saw a mild negative market reaction to this news.",
      "banner_image": "https://www.globenewswire.com/newsroom/ti?nf=OTU3OTI5MiM3Mjc0MzQxIzIyOTk1MzM=",
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.028604,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ICU",
          "relevance_score": "0.332363",
          "ticker_sentiment_score": "0.042037",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "SeaStar Medical Holding Corporation (NASDAQ:ICU) Q3 2025 Earnings Call Transcript",
      "url": "https://www.insidermonkey.com/blog/seastar-medical-holding-corporation-nasdaqicu-q3-2025-earnings-call-transcript-1647516/",
      "time_published": "20251117T100947",
      "authors": [
        "NULL"
      ],
      "summary": "SeaStar Medical Holding Corporation reported its Q3 2025 financial results, with net revenue of $183,000 and a 92% gross profit margin. The company is advancing its Quellimmune therapy, expanding its customer base in pediatric hospitals, and progressing with its neutralized AKI and newly launched neutralized CRS clinical trials. Despite an increase in the target enrollment for the AKI trial to 339 patients, the company is confident in achieving this by December 2026 and anticipates over $1 million in revenue for the full year 2025.",
      "banner_image": "https://imonkey-blog.imgix.net/blog/wp-content/uploads/2023/11/22153449/ICU-insidermonkey-1700685287482.jpg?auto=format&fit=clip&expires=1796688000&width=480&height=269",
      "source": "Insider Monkey",
      "category_within_source": "General",
      "source_domain": "Insider Monkey",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.917683"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.845378"
        }
      ],
      "overall_sentiment_score": 0.486909,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ICU",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.464221",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "SeaStar Medical (Nasdaq: ICU) names CFO Michael Messinger, 25-year healthcare finance leader",
      "url": "https://www.stocktitan.net/news/ICU/sea-star-medical-announces-appointment-of-michael-messinger-as-u869gntmlk1l.html",
      "time_published": "20251117T100937",
      "authors": [],
      "summary": "SeaStar Medical (Nasdaq: ICU) has appointed Michael Messinger as its new Chief Financial Officer, bringing over 25 years of healthcare finance experience. Messinger's background includes leading ContraFect's Nasdaq IPO and managing a $90 million BARDA contract, which SeaStar Medical expects will be invaluable as it expands commercial operations for its QUELIMMUNE (SCD-PED) therapy. His appointment is aimed at strengthening the company's financial and operational leadership during a period of growth and expansion into new indications.",
      "banner_image": "https://ml.globenewswire.com/media/ODQyZmY2ZWUtNGQzNi00OGYyLThlOTYtYjJjMGI4NGM3OWY1LTEzMTEwODMtMjAyNS0xMS0xNy1lbg==/tiny/SeaStar-Medical.png",
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.929151"
        },
        {
          "topic": "finance",
          "relevance_score": "0.848330"
        },
        {
          "topic": "ipo",
          "relevance_score": "0.703138"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.642826"
        }
      ],
      "overall_sentiment_score": -0.087642,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ICU",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.268448",
          "ticker_sentiment_label": "Somewhat-Bearish"
        },
        {
          "ticker": "PFE",
          "relevance_score": "0.593901",
          "ticker_sentiment_score": "0.148409",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "SeaStar Medical appoints Michael Messinger as new CFO",
      "url": "https://www.investing.com/news/company-news/seastar-medical-appoints-michael-messinger-as-new-cfo-93CH-4362472",
      "time_published": "20251117T084900",
      "authors": [
        "Investing.com"
      ],
      "summary": "SeaStar Medical Holding Corporation has appointed Michael Messinger as its new Chief Financial Officer, bringing over 25 years of healthcare industry experience. Messinger's previous roles include leading ContraFect Corporation through its Nasdaq IPO and securing significant financing. SeaStar Medical focuses on treatments for critically ill patients with organ failure, currently conducting trials for its SCD therapy and having recently reported increased net revenue in Q3 2025.",
      "banner_image": "https://i-invdn-com.investing.com/news/news_six_pile_69x52._800x533_L_1419494215.jpg",
      "source": "Investing.com",
      "category_within_source": "General",
      "source_domain": "Investing.com",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.900493"
        },
        {
          "topic": "finance",
          "relevance_score": "0.840230"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.700669"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.643965"
        }
      ],
      "overall_sentiment_score": 0.497189,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ICU",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.481483",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "SeaStar Medical Announces Appointment of Michael Messinger as CFO",
      "url": "https://www.globenewswire.com/news-release/2025/11/17/3189179/0/en/SeaStar-Medical-Announces-Appointment-of-Michael-Messinger-as-CFO.html",
      "time_published": "20251117T084300",
      "authors": [],
      "summary": "SeaStar Medical Holding Corporation (Nasdaq: ICU) has announced the appointment of Michael Messinger as its new Chief Financial Officer. Messinger brings over 25 years of healthcare industry experience, including leading ContraFect Corporation through its Nasdaq IPO and securing significant financing. His expertise is expected to be invaluable as SeaStar Medical expands its commercial operations for its SCD therapy.",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/af3b94e5-5da2-4c11-8e6a-749a5f74152d/image1.gif",
      "source": "GlobeNewswire",
      "category_within_source": "General",
      "source_domain": "GlobeNewswire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.906675"
        },
        {
          "topic": "finance",
          "relevance_score": "0.726391"
        }
      ],
      "overall_sentiment_score": 0.43282,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ICU",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.439506",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "SeaStar Medical Reports Significant Progress in QUELIMMUNE Therapy Adoption and Financial Results for Third Quarter 2025",
      "url": "https://www.quiverquant.com/news/SeaStar+Medical+Reports+Significant+Progress+in+QUELIMMUNE+Therapy+Adoption+and+Financial+Results+for+Third+Quarter+2025",
      "time_published": "20251113T091500",
      "authors": [
        "NULL"
      ],
      "summary": "SeaStar Medical announced significant progress in the third quarter of 2025, including the adoption of its QUELIMMUNE therapy by three top-rated children's hospitals and positive survival data for pediatric patients with acute kidney injury. The company also strengthened its financial position with a $12.4 million funding round and reported a reduced net loss, while expanding its NEUTRALIZE-AKI pivotal clinical trial for adults.",
      "banner_image": "https://www.quiverquant.com/images/icu_rect_new.png",
      "source": "Quiver Quantitative",
      "category_within_source": "General",
      "source_domain": "Quiver Quantitative",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.945083"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.844462"
        }
      ],
      "overall_sentiment_score": 0.234154,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ICU",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.486870",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "PNC",
          "relevance_score": "0.641618",
          "ticker_sentiment_score": "0.124648",
          "ticker_sentiment_label": "Neutral"
        },
        {
          "ticker": "V",
          "relevance_score": "0.573303",
          "ticker_sentiment_score": "0.126615",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "SeaStar Medical (NASDAQ: ICU) sets third-quarter call for Nov. 13 at 4:30 p.m. ET",
      "url": "https://www.stocktitan.net/news/ICU/sea-star-medical-to-report-third-quarter-financial-results-on-xi7r22z50kb5.html",
      "time_published": "20251113T080943",
      "authors": [
        "NULL"
      ],
      "summary": "SeaStar Medical (NASDAQ: ICU) announced it will report Q3 2025 financial results after market close on Thursday, November 13, 2025, and will host a webcast and conference call at 4:30 p.m. ET. The company will discuss its financial results and business progress, including updates on its FDA-approved QUELIMMUNE (SCD-PED) therapy for pediatric AKI and its pivotal adult AKI trial.",
      "banner_image": "NULL",
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.903741"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.847991"
        }
      ],
      "overall_sentiment_score": 0.077114,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ICU",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.078590",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "SeaStar Medical to Report Third Quarter Financial Results on November 13, 2025",
      "url": "https://finance.yahoo.com/news/seastar-medical-report-third-quarter-150300435.html",
      "time_published": "20251105T041056",
      "authors": [],
      "summary": "SeaStar Medical Holding Corporation announced it will report its third quarter financial results after market close on Thursday, November 13, 2025. The company will also host a webcast and conference call to discuss its financial results and business progress. SeaStar Medical focuses on treatments for critically ill patients facing organ failure, with its QUELIMMUNE (SCD-PED) therapy being FDA-approved for acute kidney injury in pediatric patients.",
      "banner_image": "https://s.yimg.com/ny/api/res/1.2/rj0Ta3GGeVAy26gXI.Thag--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIyNDtoPTQ4O2cfcHdlYnA-/https://s.yimg.com/os/creatr-uploaded-images/2025-08/b2b7bbc0-8385-11f0-977e-d9d7d4cd04d2",
      "source": "Yahoo Finance",
      "category_within_source": "General",
      "source_domain": "Yahoo Finance",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "1.000000"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.905682"
        }
      ],
      "overall_sentiment_score": 0.029046,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ICU",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.037300",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "First Real-World Data: SeaStar Medical's QUELIMMUNE Treatment for Critical Pediatric Kidney Injury",
      "url": "https://www.stocktitan.net/news/ICU/sea-star-medical-to-present-early-save-registry-data-of-quelimmune-2dqrt04lpofz.html",
      "time_published": "20250923T082300",
      "authors": [],
      "summary": "SeaStar Medical will present preliminary results from its SAVE Surveillance Registry for QUELIMMUNE therapy at the 5th International Symposium on Acute Kidney Injury in Children on September 27, 2025. The registry collects Real-World Evidence from up to 300 pediatric patients with acute kidney injury (AKI) and sepsis, focusing on 90-day survival, dialysis dependency, and safety data. QUELIMMUNE, approved in February 2024, is designed to treat critical pediatric AKI and has shown a 77% survival rate in previous studies.",
      "banner_image": null,
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.931095"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.726065"
        }
      ],
      "overall_sentiment_score": 0.404418,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ICU",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.419853",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Critical Care Biotech SeaStar Medical to Present Latest Organ Failure Treatment Updates at HC Wainwright Conference",
      "url": "https://www.stocktitan.net/news/ICU/sea-star-medical-to-participate-in-the-hc-wainwright-27th-annual-c7uyb0ap5t4z.html",
      "time_published": "20250904T181300",
      "authors": [],
      "summary": "SeaStar Medical (Nasdaq: ICU), a commercial-stage healthcare company focused on organ failure treatments, announced its participation in the HC Wainwright 27th Annual Global Investment Conference. The company's presentation is scheduled for September 5, 2025, at 7:00 am ET and will be accessible via their Investor Relations section for 60 days. SeaStar Medical specializes in the QUELIMMUNE (SCD-PED) therapy for critical pediatric AKI and is currently conducting a pivotal trial for its SCD therapy in adult AKI patients.",
      "banner_image": null,
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.030753,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ICU",
          "relevance_score": "0.339927",
          "ticker_sentiment_score": "0.005694",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "SeaStar Medical Holding Corporation Announces Registered Direct Offering of Common Stock and Concurrent Private Placement",
      "url": "https://www.quiverquant.com/news/SeaStar+Medical+Holding+Corporation+Announces+Registered+Direct+Offering+of+Common+Stock+and+Concurrent+Private+Placement",
      "time_published": "20250731T191000",
      "authors": [],
      "summary": "SeaStar Medical Holding Corporation announced a registered direct offering of 4.96 million shares of common stock at $0.887 each, aiming to raise approximately $4.4 million for general corporate purposes. Concurrently, the company is issuing unregistered warrants to purchase the same number of shares. The offering, facilitated by H.C. Wainwright & Co., is expected to close around August 1, 2025.",
      "banner_image": null,
      "source": "Quiver Quantitative",
      "category_within_source": "General",
      "source_domain": "Quiver Quantitative",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "1.000000"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.908666"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.840802"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.721864"
        }
      ],
      "overall_sentiment_score": -0.12595,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "ICU",
          "relevance_score": "0.989892",
          "ticker_sentiment_score": "-0.138622",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Economic Analysis Supporting Significant Hospitalization Cost Reduction with SeaStar Medical\u2019s QUELIMMUNE Pediatric Therapeutic Device Presented at ASN Kidney Week 2024",
      "url": "https://www.stocktitan.net/news/ICU/economic-analysis-supporting-significant-hospitalization-cost-sr1b9flb451a.html",
      "time_published": "20241025T083000",
      "authors": [],
      "summary": "SeaStar Medical presented economic analysis data for its QUELIMMUNE device at ASN Kidney Week 2024, demonstrating significant cost savings and improved survival rates for pediatric acute kidney injury (AKI) patients. The analysis showed a potential savings of approximately $30,000 per hospitalization, with cost neutrality achieved after 6 days of therapy, and a 77% survival rate for children treated with QUELIMMUNE compared to 50% with standard care. The company also highlighted ongoing trials for NEUTRALIZE-AKI and NEUTRALIZE-CRS, expanding the therapeutic applications of its Selective Cytopheretic Device (SCD).",
      "banner_image": null,
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.404817,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ICU",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.402199",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "SeaStar Medical Provides Updates on Enrollment of Adult Pivotal Clinical Study and Commercial Launch of Quelimmune, FDA-Approved in Pediatric Patients",
      "url": "https://www.stocktitan.net/news/ICU/sea-star-medical-provides-updates-on-enrollment-of-adult-pivotal-tiuxb8uxsxoc.html",
      "time_published": "20240312T083000",
      "authors": [],
      "summary": "SeaStar Medical is providing updates on its acute kidney injury (AKI) programs, including the enrollment progress of its NEUTRALIZE-AKI pivotal clinical trial for adult AKI patients, which has 21 subjects across five sites. The company also announced the commercial launch of Quelimmune, its FDA-approved pediatric device for AKI in children weighing 10 kilograms or more. SeaStar Medical plans to hold a business update conference call in April to discuss further progress and opportunities.",
      "banner_image": null,
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.934327"
        }
      ],
      "overall_sentiment_score": 0.217103,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ICU",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.335832",
          "ticker_sentiment_label": "Somewhat-Bullish"
        },
        {
          "ticker": "GEHC",
          "relevance_score": "0.611406",
          "ticker_sentiment_score": "0.105423",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "FDA Grants Breakthrough Device Designation to SeaStar Medical\u2019s Selective Cytopheretic Device for Cardiorenal Syndrome",
      "url": "https://www.stocktitan.net/news/ICU/fda-grants-breakthrough-device-designation-to-sea-star-medical-s-9cz9vi84uexq.html",
      "time_published": "20230929T083000",
      "authors": [
        "NULL"
      ],
      "summary": "SeaStar Medical Holding Corporation received Breakthrough Device Designation from the FDA for its Selective Cytopheretic Device (SCD) for patients with cardiorenal syndrome. This designation aims to expedite the device's clinical development and regulatory review. The SCD targets hyperinflammation in critically ill patients, with preclinical data and a successful first-in-human study supporting its potential.",
      "banner_image": "NULL",
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.948960"
        }
      ],
      "overall_sentiment_score": 0.495309,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ICU",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.480307",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "SeaStar Medical Provides Regulatory Update Related to its HDE Application for Pediatric Selective Cytopheretic Device",
      "url": "https://www.stocktitan.net/news/ICU/sea-star-medical-provides-regulatory-update-related-to-its-hde-s2jg29htgxe4.html",
      "time_published": "20230509T160500",
      "authors": [],
      "summary": "SeaStar Medical announced that its Humanitarian Device Exemption (HDE) application for its pediatric Selective Cytopheretic Device (SCD) was not approved by the FDA in its current form. While disappointed, the company believes the cited deficiencies are addressable and plans to request administrative review and appeal if necessary. SeaStar Medical will also continue working with CBER to achieve pediatric HDE approval, noting that this decision does not impact the ongoing pivotal clinical trial for SCD in adults with AKI.",
      "banner_image": null,
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.948367"
        }
      ],
      "overall_sentiment_score": -0.405165,
      "overall_sentiment_label": "Bearish",
      "ticker_sentiment": [
        {
          "ticker": "ICU",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.432571",
          "ticker_sentiment_label": "Bearish"
        }
      ]
    },
    {
      "title": "SeaStar Medical Completes Business Combination with LMF Acquisition Opportunities",
      "url": "https://www.globenewswire.com/news-release/2022/10/28/2544090/0/en/SeaStar-Medical-Completes-Business-Combination-with-LMF-Acquisition-Opportunities.html",
      "time_published": "20221028T132000",
      "authors": [],
      "summary": "SeaStar Medical, Inc. has completed its business combination with LMF Acquisition Opportunities, Inc., forming SeaStar Medical Holding Corporation. The combined entity's common stock and warrants will commence trading on Nasdaq under the ticker symbols \"ICU\" and \"ICUCW\" on October 31, 2022. This merger provides SeaStar Medical with greater resources to advance its Selective Cytopheretic Device (SCD) for hyperinflammation, including plans for a pivotal study in adults with acute kidney injury in early 2023.",
      "banner_image": null,
      "source": "GlobeNewswire",
      "category_within_source": "General",
      "source_domain": "GlobeNewswire",
      "topics": [
        {
          "topic": "mergers_and_acquisitions",
          "relevance_score": "1.000000"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.918440"
        },
        {
          "topic": "finance",
          "relevance_score": "0.710407"
        }
      ],
      "overall_sentiment_score": 0.402319,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "ICU",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.446282",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    }
  ]
}